States are legalizing psilocybin — the psychoactive compound found in certain mushrooms — because a growing body of clinical evidence suggests it can treat depression, anxiety, and PTSD in ways that conventional medications cannot, and doctors working with it are reporting rapid, durable improvements in patients who had exhausted every other option. Oregon became the first state to legalize regulated psilocybin therapy in 2020, and Colorado followed in 2022. Since then, more than a dozen other states have introduced legislation to either decriminalize or create therapeutic access programs, driven largely by a mental health crisis that existing treatments have failed to contain.
What makes this relevant to brain health and dementia care is that researchers are now investigating whether psilocybin’s ability to promote neuroplasticity — the brain’s capacity to form new neural connections — could benefit people experiencing cognitive decline. Early-stage trials at Johns Hopkins and Imperial College London have shown that psilocybin increases connectivity between brain regions that typically become isolated as dementia progresses. This article examines why the legal landscape is shifting, what clinical results doctors are actually seeing, the specific implications for brain health and caregiving, and the serious limitations and risks that remain part of the conversation.
Table of Contents
- Why Are States Moving to Legalize Psilocybin, and What Are Doctors Reporting?
- What the Clinical Evidence Actually Shows — and Where It Falls Short
- Psilocybin and the Aging Brain — What Neuroplasticity Research Suggests
- How Psilocybin Therapy Compares to Other Emerging Brain Health Treatments
- Risks, Drug Interactions, and Why Unsupervised Use Is Dangerous for Older Adults
- What Legal Access Actually Looks Like in Practice
- Where the Research Is Heading and What Families Should Watch For
- Conclusion
- Frequently Asked Questions
Why Are States Moving to Legalize Psilocybin, and What Are Doctors Reporting?
The short answer is that the data became too compelling to ignore while the mental health system was buckling under demand. Between 2019 and 2024, treatment-resistant depression diagnoses in the United States rose by roughly 30 percent, according to data from the National Institute of Mental Health. Standard antidepressants — SSRIs like sertraline and escitalopram — fail to produce adequate remission in about one-third of patients, and for older adults, the side effect profiles often include cognitive blunting, falls, and hyponatremia. When clinical trials began showing that a single guided psilocybin session could reduce depression scores by 50 percent or more for weeks or months, legislators in states with progressive healthcare agendas started paying attention. Doctors who have administered psilocybin in clinical and research settings describe outcomes they rarely see with other interventions. Dr. Matthew Johnson, who led psilocybin research at Johns Hopkins before moving to other academic roles, has noted that patients frequently describe the experience as among the most meaningful of their lives, comparable to the birth of a child or the death of a parent.
This is not hyperbole from enthusiasts — it is a consistent finding in published research. Clinicians report that patients with terminal illness-related anxiety, in particular, show dramatic reductions in existential distress after just one or two sessions, with effects persisting at six-month and twelve-month follow-ups. The legislative momentum is also fueled by frustration with the slow pace of federal drug scheduling reform. The DEA still classifies psilocybin as Schedule I, meaning it officially has “no accepted medical use,” a designation that most researchers in the field now consider scientifically indefensible. States are not waiting. Oregon’s Measure 109 created a framework for licensed service centers where adults can receive psilocybin under supervision. Colorado’s Proposition 122 went further, decriminalizing personal possession and use while also establishing a regulated therapeutic access program. Connecticut, new York, California, and several others have active bills in various stages.
What the Clinical Evidence Actually Shows — and Where It Falls Short
The most robust data comes from randomized controlled trials on major depressive disorder and end-of-life anxiety. A 2022 study published in the New England Journal of Medicine compared psilocybin to escitalopram over six weeks and found that while both reduced depression scores, psilocybin worked faster and patients reported better quality of life and emotional connectivity. A landmark 2016 trial at NYU, published in the Journal of Psychopharmacology, found that a single psilocybin dose reduced anxiety and depression in cancer patients, with 80 percent still showing clinically significant improvement at the six-month mark. However, there is a critical caveat that often gets lost in popular coverage: nearly all of these studies involve carefully screened participants receiving psilocybin in controlled settings with trained therapists before, during, and after the session. People with a personal or family history of psychotic disorders such as schizophrenia are excluded from trials because psilocybin can trigger psychotic episodes.
Individuals taking lithium are also excluded due to the risk of seizures. If someone with undiagnosed Lewy body dementia — a condition that already involves visual hallucinations — were to take psilocybin unsupervised, the results could be dangerous and destabilizing rather than therapeutic. The other limitation is that “treatment-resistant” in these studies usually means the patient has tried two or more antidepressants without success, but the populations studied tend to be younger and cognitively intact. Very few trials have enrolled adults over 65, and almost none have included participants with any form of cognitive impairment. this means the evidence base, while genuinely impressive for certain conditions, cannot yet be generalized to the dementia care population without significant assumptions.
Psilocybin and the Aging Brain — What Neuroplasticity Research Suggests
The reason neuroscientists are interested in psilocybin for brain health goes beyond mood. Psilocybin’s primary mechanism of action involves the 5-HT2A serotonin receptor, and its activation triggers a cascade that increases brain-derived neurotrophic factor, or BDNF. BDNF is essentially fertilizer for neurons — it supports the growth and survival of nerve cells and facilitates the formation of new synaptic connections. In Alzheimer’s disease, BDNF levels in the hippocampus and cortex are significantly reduced, which is one reason memory and learning deteriorate.
A 2023 study from the University of Southern Denmark, published in Molecular Psychiatry, demonstrated that a single dose of psilocybin in mice increased dendritic spine density — the tiny protrusions on neurons where synapses form — by roughly 10 percent in the frontal cortex, and that this increase persisted for at least a month. While mouse studies do not translate directly to humans, the finding was notable because most existing Alzheimer’s drugs do nothing to promote new neural connections; they merely slow the degradation of existing ones, and they do so modestly. A small pilot study at the University of California, San Francisco is currently investigating psilocybin-assisted therapy in patients with mild cognitive impairment, a condition that often precedes Alzheimer’s. Preliminary results have not yet been published, but the study’s principal investigator has stated publicly that the primary outcome measures include not just mood and anxiety scores but also cognitive testing and neuroimaging to assess changes in functional brain connectivity. This is the kind of trial that could either validate or temper the enthusiasm around psilocybin’s relevance to dementia.
How Psilocybin Therapy Compares to Other Emerging Brain Health Treatments
Psilocybin is not the only compound generating interest in the neuroplasticity and dementia research space, and understanding how it compares to alternatives helps clarify its potential role. Ketamine, which is already FDA-approved in a nasal spray form (esketamine, marketed as Spravato) for treatment-resistant depression, also promotes neuroplasticity and has been studied in older adults. However, ketamine requires repeated dosing — typically twice a week initially, then tapering to weekly or biweekly — and its effects tend to fade within days to weeks of stopping. Psilocybin’s advantage, based on current evidence, is that a single session can produce effects lasting months, which reduces the cumulative burden on patients and healthcare systems. On the pharmaceutical side, the newer Alzheimer’s drugs lecanemab (Leqembi) and donanemab target amyloid plaques directly. They represent a fundamentally different approach — clearing pathological protein deposits rather than enhancing neural connectivity.
These drugs have shown statistically significant but clinically modest benefits, slowing cognitive decline by about 27 to 35 percent over 18 months. They also carry serious risks, including brain swelling and microbleeds. Psilocybin, if it proves useful for cognitive health, would likely work through a complementary mechanism rather than a competing one — addressing neural connectivity and the psychological burden of cognitive decline rather than the underlying amyloid pathology. The tradeoff is clarity of evidence versus novelty of mechanism. Lecanemab has completed Phase 3 trials with thousands of participants. Psilocybin’s cognitive benefits in older adults remain hypothetical, supported by mechanistic plausibility and animal data rather than large human trials. Families and caregivers weighing these options should understand that psilocybin is much earlier in the evidence pipeline for dementia specifically, even though its evidence for depression and anxiety is strong.
Risks, Drug Interactions, and Why Unsupervised Use Is Dangerous for Older Adults
The enthusiasm around psilocybin has created a real public safety concern, particularly for older adults and people with cognitive impairment. Psilocybin’s interaction with serotonergic medications is poorly characterized but potentially dangerous. Many older adults take SSRIs or SNRIs for depression, trazodone for sleep, or triptans for migraines — all of which affect the serotonin system. Combining psilocybin with these drugs can blunt its therapeutic effects at best or, in rare cases, contribute to serotonin syndrome, a potentially life-threatening condition involving agitation, rapid heart rate, high blood pressure, and hyperthermia. There is also the issue of cardiovascular risk. Psilocybin modestly increases heart rate and blood pressure during the acute experience, typically lasting four to six hours. For a healthy 35-year-old in a clinical trial, this is medically insignificant.
For a 78-year-old with atrial fibrillation, uncontrolled hypertension, or a history of stroke, it introduces a risk that has not been studied. No clinical trial has yet established cardiovascular safety parameters for psilocybin in the elderly population. Perhaps the most underappreciated risk is psychological. Psilocybin can produce intense emotional and perceptual experiences, including reliving traumatic memories, experiencing ego dissolution, and confronting existential fear. In a supported therapeutic setting with trained facilitators, these experiences are generally processed constructively. For a person with moderate dementia who cannot fully understand what is happening, lacks the cognitive framework to process the experience, or cannot communicate distress effectively, the same experience could be terrifying. Any caregiver or family member considering psilocybin for a loved one with cognitive impairment should understand that the therapeutic context — not just the molecule — is what makes the difference between a healing experience and a harmful one.
What Legal Access Actually Looks Like in Practice
Oregon’s psilocybin service centers, which began accepting clients in mid-2023, offer a useful window into how regulated access works. A client must be at least 21 years old, attend a preparation session with a licensed facilitator, undergo the psilocybin session at an approved center (sessions typically last five to six hours and involve 25 milligrams of synthetic psilocybin), and then complete an integration session afterward. The cost ranges from roughly 1,500 to 3,500 dollars per session, and health insurance does not cover it. There is no requirement for a medical diagnosis, a physician referral, or a mental health evaluation — a deliberate choice by Oregon regulators who wanted to avoid gatekeeping but one that has drawn criticism from clinicians who believe medical screening should be mandatory.
Colorado’s program, still being finalized through its regulatory process, is expected to require more clinical oversight. Several other states considering legislation are debating whether psilocybin should be available only through healthcare providers or through the broader wellness-center model Oregon adopted. For older adults and their families, the practical question is whether any of these frameworks currently accommodate people with cognitive impairment — and as of now, the answer is largely no. No state program has developed specific protocols, screening tools, or safety guidelines for administering psilocybin to individuals with dementia or mild cognitive impairment.
Where the Research Is Heading and What Families Should Watch For
The next three to five years will likely determine whether psilocybin becomes a legitimate tool in the dementia care landscape or remains limited to mood and anxiety disorders. The FDA granted psilocybin “breakthrough therapy” designation for treatment-resistant depression in 2018, which accelerates the review process. If the ongoing Phase 3 trials by companies like COMPASS Pathways yield positive results, FDA approval for depression could come within the next few years, which would open the door for off-label use in other populations, including older adults with cognitive decline.
The research to watch is not just the big depression trials but the smaller mechanistic studies examining psilocybin’s effects on neuroinflammation, tau protein accumulation, and default mode network connectivity in aging brains. If psilocybin can demonstrably reduce neuroinflammation — a key driver of Alzheimer’s progression — its relevance to dementia care would shift from speculative to substantive. For families navigating the current landscape, the responsible position is one of informed optimism: this is a genuinely promising area of research with legitimate scientific foundations, but it is not yet ready for clinical application in cognitively impaired populations, and anyone offering it as a dementia treatment today is outrunning the evidence.
Conclusion
States are legalizing psilocybin because the clinical evidence for treating depression, anxiety, and existential distress has reached a threshold that lawmakers can no longer dismiss, particularly against the backdrop of a national mental health crisis and widespread dissatisfaction with existing treatments. For the brain health and dementia care community, the neuroplasticity-promoting properties of psilocybin add another dimension of interest — one that is scientifically grounded but not yet clinically validated for cognitive decline. What families and caregivers should take from this is a balanced awareness.
Psilocybin is not a fringe substance championed only by counterculture advocates; it is being studied at the most respected research institutions in the world, and the results for mood disorders are genuinely striking. But the gap between “promising for depression in healthy adults” and “safe and effective for people with dementia” is wide, and crossing it requires years of careful research. Stay informed, ask your loved one’s neurologist about emerging trials, and be deeply skeptical of anyone — whether a wellness center, a supplement company, or an online forum — claiming that psilocybin can treat or reverse dementia today.
Frequently Asked Questions
Is psilocybin legal everywhere in the United States?
No. As of early 2026, psilocybin remains a Schedule I controlled substance under federal law. Oregon and Colorado have created state-level frameworks for legal therapeutic or supervised use, and several other states have introduced decriminalization or legalization bills, but most states still classify it as illegal. Legal status can change quickly, so check your state’s current laws before taking any action.
Can psilocybin reverse or cure Alzheimer’s disease?
There is no evidence that psilocybin can reverse or cure Alzheimer’s or any other form of dementia. Animal studies and early human research suggest it may promote neuroplasticity, which is relevant to brain health, but no clinical trial has demonstrated cognitive improvement in dementia patients. Anyone marketing psilocybin as a dementia cure is making claims unsupported by science.
Is it safe for someone with dementia to try psilocybin?
This has not been established. Clinical trials have largely excluded older adults with cognitive impairment, and the psychological intensity of psilocybin experiences raises specific concerns for people who may not be able to understand, process, or communicate what they are going through. Drug interactions with common medications taken by older adults are also poorly understood. Medical supervision and a conversation with a knowledgeable physician are essential before considering any use.
How much does a legal psilocybin session cost?
In Oregon, where regulated psilocybin services became available in 2023, a single session costs between approximately 1,500 and 3,500 dollars. This includes preparation, the supervised session itself, and an integration session afterward. Health insurance does not currently cover psilocybin therapy anywhere in the United States.
What is the difference between psilocybin therapy and microdosing?
Psilocybin therapy involves a full, perceptually significant dose administered in a supported clinical setting with preparation and integration. Microdosing involves taking a sub-perceptual amount — typically one-tenth to one-twentieth of a full dose — on a regular schedule. The clinical evidence supporting therapeutic benefits comes almost entirely from full-dose studies. Research on microdosing has produced mixed results, with some studies suggesting the reported benefits may be driven by placebo effects rather than pharmacological action.
